FAU College Collections
Displaying 1 - 1 of 1
Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential
Type: Text
Year: 2016, 2016
Member of: FAU College Collections
Contributors: Barberena, Roberto, Cheung, Wan Cheung, Chu, Isabel M., Cudic, Mare, Finn, Olivera J., Ham, James D., Innocenti, Gregory M., Lohmueller, Jason J., Polakiewicz, Roberto D., Popova, Lana, Sato, Shuji, Tucker, Meghan A.
Description: MUC1 is a shared tumor antigen expressed on >80% of human cancers. We completed the first
prophylactic cancer vaccine clinical trial based on a non-viral antigen, MUC1, in healthy individuals
at-risk for colon cancer. This trial provided a unique source of potentially effective and safe
immunotherapeutic drugs, fully-human antibodies affinity-matured in a healthy host to a tumor
antigen.… more
Full Text: www.nature.com/scientificreports OPEN received: 15 June 2016 accepted: 25 July 2016 Published: 22 August 2016 Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential Jason J. …